摘要
[目的]探讨来氟米特联合糖皮质激素治疗难治性肾病综合征（RNS）的临床疗效及其安全性.[方法]63例RNS患者随机分为观察组（32例）和对照组（31例）,在糖皮质激素治疗的基础上两组分别加用来氟米特和环磷酰胺,持续12个月.对比观察两组的临床疗效、生化指标变化以及药物不良反应.[结果]两组治疗后24 h尿蛋白定量、三酰甘油和胆固醇水平均明显降低,白蛋白水平则显著升高,与治疗前比较差异有显著性（P＜0.05）;两组间比较,观察组24 h尿蛋白定量和白蛋白水平变化更为明显,差异有显著性（P＜0.05）;观察组总有效率为84.4%,对照组总有效率为74.2%,组间比较差异无显著性（P＞0.05）.用药期间观察组总不良反应发生率为15.6%,明显低于对照组（38.7%）,差异有显著性（P＜0.05）.[结论]来氟米特联合糖皮质激素治疗RNS具有较好的疗效,耐受性好,不良反应轻,值得临床推广应用.
[Objective]To explore the clinical efficacy and safety of leflunomide combined with glucocorticoid for the treatment of refractory nephrotie syndrome.[Methods] Totally 63 patients with refractory nephrotic syndrome were ran- domly divided into observation group（ n =32） and control group（ n= 31）. All patients received leflunomide and cyclo phosphamide respectively on the basis of steroid therapy and sustained for 12 months. The clinical efficacy, the change of biochemical indicators and drug adverse reactions were observed and compared between two groups. [Results]After treat ment, the 24h urinary protein, triglyceride and cholesterol levels of both groups decreased significantly, while the albumin level increased significantly, and there was significant difference between before and after treatment（ P 〈0.05）. The 24h urine protein and albumin levels in observation group changed more obviously than those in control group, and there was significant difference between two groups （ P 〈0.05）. The total effective rate of observation group and control group was 84.4% and 74.2%, respectively, but there was no significant difference between two groups （ P 〉0.05）. The total incidence rate of adverse reactions of observation group and control group was 15.6% and 38.7%, respectively, and there was significant difference between two groups（ P 〈0.05）. [Conelusion]Leflunomide combined with glucocorticoid for the treatment of refractory nephrotic syndrome has good effect and tolerance with less adverse reactions, so it is worthy of clinical application.
出处
《医学临床研究》
CAS
2011年第3期507-509,共3页
Journal of Clinical Research
